Rosemarie Mick, MS

Rosemarie Mick is Senior Research Investigator and Adjunct Associate Professor of Biostatistics. She joined the Department in 1996, after serving eight years, first as Research Associate and then Lecturer, in the Department of Medicine and Committee on Clinical Pharmacology, at the University Of Chicago School Of Medicine. This position was preceded by four years as Research Associate in the Department of Biostatistics at the Harvard School of Public Health and Division of Biostatistics at the Dana-Farber Cancer Institute. Ms. Mick has been continuously involved in cancer research for more than thirty years and has over 200 cancer-related publications. Her research interests include clinical trial methodology and development of anti-cancer immunotherapies and targeted therapies. Ms. Mick has served as Permanent Member of the Experimental Therapeutics 2 [ET-2] and Cancer Immunopathology and Immunotherapy [CII] Study Sections of the Center for Scientific Review at NIH. She has served 5 terms on the faculty of the AACR/ASCO Methods in Clinical Cancer Research Workshop (Vail, CO) and 4 terms on the faculty of the tandem European-based ECCO/AACR/EORTC/ESMO Workshop (Flims, Switzerland). She recently organized an invited paper session entitled Statistical Challenges in Immuno-Oncology at the 2016 annual meeting of the Society for Clinical Trials. She has served as Section Editor for Biostatistics for the high impact oncology journal, Clinical Cancer Research and is currently Senior Editor for the highly respected journal Cancer Immunology Research.

Selected Publications

  1. Clark C, Hingorani S, Mick R, Combs C, Tuveson D and Vonderheide R. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Research 67: 9518-9527, 2007.
  2. Domchek S, Recio A, Mick R, Clark C, Carpenter E, Fox K, DeMichele A, Schuchter L, Leibowitz M, Wexler M, Vance B, Beatty G, Veloso E, Feldman M and Vonderheide R. Telomerase-specific T-cell immunity in breast cancer: impact of active vaccination on tumor immunosurveillance. Cancer Research 67:10546-10555, 2007.
  3. Carpenter E, Mick R, Ruter J and Vonderheide R. Activation of human B cells by the agonist CD40 antibody CP-870,893 and enhancement with simultaneous toll-like receptor 9 stimulation. Journal of Translational Medicine 7:1-10, 2009.
  4. Rech A, Mick R, Kaplan D, Chang K-M, Domchek S and Vonderheide R. Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 59:599-6078, 2010.
  5. Li Y, Mick R, Heitjan D: A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials. Clinical Trials 9(3): 293-302, 2012.
  6. Rech A, Mick R, Martin S, Recio A, Aqui N, Powell D, Colligon T, Trosko J, Leinbach L, Pletcher C, Tweed C, DeMichele A, Fox K, Domchek S, Riley J and Vonderheide R: CD25 blockade depletes and selectively reprograms regulatory T-cells and cooperates with immunotherapy in cancer patients. Science Translational Medicine 4:134ra62, 2012.
  7. Reshef R, Luger S, Hexner E, Loren A, Frey N, Nasta S, Goldstein S, Stadtmauer E, Smith J, Bailey S, Mick R, Heitjan D, Emerson S, Hoxie J, Vonderheide R and Porter D: Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease. New England Journal of Medicine 367:135-145, 2012.
  8. Vonderheide R, Burg J, Mick R, Trosko J, Huhn R, Li D, Shaik N, Tolcher A and Hamid O: Phase I study of CD40 antibody CP-870,893 in combination with carboplatin and paclitaxel in patients with advanced solid tumors. OncoImmunology 2:1-10, 2013.
  9. Li Y, Mick R and Heitjan D: Suspension of accrual in phase II cancer clinical trials. Clinical Trials 12:128-138, 2015.
  10. Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, Benci J, Xu B, Dada H, Odiorizzi P, Herati R, Mansfield K, Patsch D, Amaravadi R, Schuchter L, Ishwaran H, Mick R, Pryma D, Xu X, Feldman M, Gangadhar T, Hahn S, Wherry EJ, Vonderheide R and Minn A: Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer. Nature 520:373-377, 2015.
  11. Yang R, Mick R, Lee K, Graves H, Nathanson K, Domchek S, Kelz R, Zhang P and Czerniecki B: DCIS in BRCA1 and BRCA2 mutation carriers: Prevalence, phenotype and expression of oncodrivers C-MET and HER3. Journal of Translational Medicine 13:335, 2015.
  12. Mick R and Chen TT: Statistical challenges in the design of late-stage cancer immunotherapy studies. Cancer Immunology at the Crossroads: Biostatistics. Cancer Immunology Research 3:1292-1298, 2015.
  13. Fernandes A, Berman A, Mick R, Both S, Lelionis K, Lukens J, Ben-Josef E, Metz J and Plastaras J: A Prospective Study of Proton Beam Reirradiation for Esophageal Cancer. International Journal of Radiation Oncology • Biology • Physics 95:483-487, 2016.
Appointment 2: 
Adjunct Associate Professor of Biostatistics